There are 7 papers on seroconversion in aging research: 5 trials and 1 observational study in people, 1 in animals.
7 papers study it46 more mention it2 findings
1 new paper in 30 daysSee all 53 papers on seroconversion
“Seroconversion to the H1N1 subunit in the older subjects was associated with higher post-vaccination numbers of plasma B cells”
- Human trial5
- Humans1
- Animals1
Interventions
1GRAD-COV2
upin humans1
1 study
GRAD-COV2
upin humans1
GRAD-COV2 induces seroconversion in humans (43 of 44 young and 45 of 45 older participants).
“seroconversion to spike protein and receptor binding domain was achieved in 43 of 44 young volunteers and in 45 of 45 older participants”
Human trialthree escalating dosesfour weeksn = 90
Science translational medicine
Associations
1Plasma B cell
upin humans1
1 study
Plasma B cell
upin humans1
Plasma B cell is associated with seroconversion in humans (response to seasonal influenza vaccination).
“Seroconversion to the H1N1 subunit in the older subjects was associated with higher post-vaccination numbers of plasma B cells”
Humansresponse to seasonal influenza vaccination
Clinical nutrition (Edinburgh, Scotland)
Latest
6 papers in 12 monthsJournal of Virology
Age-Related Susceptibility of Ferrets to SARS-CoV-2 Infection
Experiments in animalsMechanisms
Science Translational Medicine
GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults
Non-randomized trial in 90 peopleCOVID-19
Trends in Biosciences Research
IMMUNE RESPONSE VARIABILITY FOLLOWING VACCINATION IN DIFFERENT AGE GROUPS
Computational studyImmune response
BMC Infectious Diseases
Telomere length dynamics in adults living with HIV: A systematic review
Systematic review of observational studiesTelomere length
Frontiers in Immunology
Immunogenicity and safety of different combinations involving a third booster dose of SARS-CoV-2 inactivated vaccine, inactivated quadrivalent influenza vaccine, and 23-valent pneumococcal polysaccharide vaccine in adults aged ≥60 years: a phase 4, randomized, open-label study
Randomized trial in 636 peopleInterventions
NPJ Vaccines
Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models
Experiments in hamstersInterventions